TT-816, A NOVEL SMALL MOLECULE IMMUNE CHECKPOINT INHIBITOR TARGETING CANNABINOID CB2 RECEPTOR, STIMULATES INNATE AND ADAPTIVE IMMUNITY FOR CANCER THERAPY

被引：0
|
作者：
Fan, Peidong [1 ]
Elzein, Elfatih [1 ]
Yao, Lina [1 ]
机构：
[1] Teon Therapeut Inc, Redwood City, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0960
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
960
引用
收藏
页码：A1001 / A1001
页数：1
相关论文
共 6 条
  • [1] Effect of TT-816, a novel immune response modifier targeting cannabinoid CB2 receptor, on antitumor immunity and cancer growth.
    Fan, Peidong
    Elzein, Elfatih
    Yao, Lina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies
    Bose, N.
    Gorden, K.
    Chan, A.
    Bykowski, A. Jonas
    Ottoson, N.
    Walsh, D.
    Qiu, X.
    Harrison, B.
    Kangas, T.
    Fraser, K.
    Fulton, R.
    Leonardo, S.
    Uhlik, M.
    Graff, J.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [3] Discovery and preclinical characterization of BAY 1905254 a novel immune checkpoint inhibitor for cancer immunotherapy targeting the immunoglobulin-like domain containing receptor 2 (ILDR2)
    Huetter, Julia
    Gritzan, Uwe
    Gutcher, Ilona
    Golfier, Sven
    Doecke, Wolf-Dietrich
    Luetke-Eversloh, Merlin Verena
    Roider, Helge
    Hunter, John
    Pow, Andrew
    Liang, Spencer
    Levine, Zurit
    Levy, Ofer
    Vaaknin, Ilan
    Kreft, Bertolt
    Roese, Lars
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer
    Zhang, Rui
    Zhu, Zhiyan
    Lv, Hongying
    Li, Futian
    Sun, Shuqing
    Li, Juan
    Lee, Chun-Sing
    SMALL, 2019, 15 (49)
  • [5] Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
    Liao, Cheng
    Hsu, Jonathan
    Kim, Yong
    Hu, Dong-Qing
    Xu, Daigen
    Zhang, Jun
    Pashine, Achal
    Menke, John
    Whittard, Toni
    Romero, Natasha
    Truitt, Theresa
    Slade, Michelle
    Lukacs, Christine
    Hermann, Johannes
    Zhou, Mingyan
    Lucas, Matthew
    Narula, Satwant
    DeMartino, Julie
    Tan, Seng-Lai
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
  • [6] Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
    Cheng Liao
    Jonathan Hsu
    Yong Kim
    Dong-Qing Hu
    Daigen Xu
    Jun Zhang
    Achal Pashine
    John Menke
    Toni Whittard
    Natasha Romero
    Theresa Truitt
    Michelle Slade
    Christine Lukacs
    Johannes Hermann
    Mingyan Zhou
    Matthew Lucas
    Satwant Narula
    Julie DeMartino
    Seng-Lai Tan
    Arthritis Research & Therapy, 15
1